The p85α regulatory subunit of PI3K mediates cAMP-PKA and retinoic acid biological effects on MCF7 cell growth and migration

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1627-1635

  Donini, Caterina F ^a   Di Zazzo, Erika ^b   Zuchegna, Candida ^c   Di Domenico, Marina ^d   D'Inzeo, Sonia ^a   Nicolussi, Arianna ^a   Avvedimento, Enrico V ^e   Coppa, Anna ^a   Porcellini, Antonio ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

cAMP; Cell growth; Cellular motility; p85 ; PI3K; RAR ; Retinoic acid

Indexed keywords

ALANINE; ASPARTIC ACID; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN P85ALPHA; RETINOIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; WOUND HEALING;

ALANINE; ANIMALS; ANTINEOPLASTIC AGENTS; ASPARTIC ACID; BREAST NEOPLASMS; CATTLE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEMALE; HUMANS; MUTATION; NEOPLASM INVASIVENESS; PHOSPHORYLATION; RECEPTORS, RETINOIC ACID; SERINE; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; TIME FACTORS; TRANSFECTION; TRETINOIN;

EID: 84860283503     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1383     Document Type: Article

References (57)

1. Cain RJ and Ridley AJ: Phosphoinositide 3-kinases in cell migration. Biol Cell 101: 13-29, 2009.
2. Sun M, Hillmann P, Hofmann BT, Hart JR and Vogt PK: Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α. Proc Natl Acad Sci USA 107: 15547-15552, 2010.
3. Bader AG, Kang S, Zhao L and Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921-929, 2005. (Pubitemid 41766781)
4. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
5. Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, et al: Somatic mutations in p85α promote tumorigenesis through class IA PI3K activation. Cancer Cell 16: 463-474, 2009.
6. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.
7. Huang CH, Mandelker D, Gabelli SB and Amzel LM: Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle 7: 1151-1156, 2008. (Pubitemid 351749265)
8. Elis W, Lessmann E, Oelgeschlager M and Huber M: Mutations in the inter-SH2 domain of the regulatory subunit of phosphoinositide 3-kinase: Effects on catalytic subunit binding and holoenzyme function. Biol Chem 387: 1567-1573, 2006. (Pubitemid 44837581)
9. Cosentino C, Di Domenico M, Porcellini A, Cuozzo C, De Gregorio G, Santillo MR, Agnese S, Di Stasio R, Feliciello A, Migliaccio A and Avvedimento EV: p85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival. Oncogene 26: 2095-2103, 2007. (Pubitemid 46514751)
10. De Gregorio G, Coppa A, Cosentino C, Ucci S, Messina S, Nicolussi A, D'Inzeo S, Di Pardo A, Avvedimento EV and Porcellini A: The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals. Oncogene 26: 2039-2047, 2007. (Pubitemid 46514747)
11. Neal CL, Xu J, Li P, Mori S, Yang J, Neal NN, Zhou X, Wyszomierski SL and Yu D: Overexpression of 14-3-3ζ in cancer cells activates PI3K via binding the p85 regulatory subunit. Oncogene: June 11, 2011 (Epub ahead of print). doi:10.1038/onc.2011.284.
12. Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464, 2005. (Pubitemid 41637985)
13. De Luca LM: Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 5: 2924-2933, 1991.
14. Sporn MB and Roberts AB: Cervical dysplasia regression induced by all-trans-retinoic acid. J Natl Cancer Inst 86: 476-477, 1994. (Pubitemid 24111001)
15. Zhu WY, Jones CS, Kiss A, Matsukuma K, Amin S and De Luca LM: Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells. Exp Cell Res 234: 293-299, 1997. (Pubitemid 27335170)
16. Wang Q, Yang W, Uytingco MS Christakos S and Wieder R: 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res 60: 2040-2048, 2000. (Pubitemid 30207668)
17. Liu Y, Lee MO, Wang HG, Li Y, Hashimoto Y, Klaus M, Reed JC and Zhang X: Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol 16: 1138-1149, 1996. (Pubitemid 26061685)
18. Zhou Q, Stetler-Stevenson M and Steeg PS: Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene 15: 107-115, 1997. (Pubitemid 27348102)
19. Agadir A, Chen G, Bost F, Li Y, Mercola D and Zhang X: Differential effect of retinoic acid on growth regulation by phorbol ester in human cancer cell lines. J Biol Chem 274: 29779-29785, 1999.
20. Masià S, Alvarez S, de Lera AR and Barettino D: Rapid, nongenomic actions of retinoic acid on phosphatidylinositol- 3-kinase signaling pathway mediated by the retinoic acid receptor. Mol Endocrinol 21: 2391-2402, 2007. (Pubitemid 47529353)
21. Lopez-Carballo G, Moreno L, Masià S, Perez P and Barettino D: Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J Biol Chem 277: 25297-25304, 2002. (Pubitemid 34951839)
22. Bastien J and Rochette-Egly C: Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 328: 1-16, 2004. (Pubitemid 38352876)
23. Ciullo I, Diez-Roux G, Di Domenico M, Migliaccio A and Avvedimento EV: cAMP signaling selectively influences Ras effectors pathways. Oncogene 20: 1186-1192, 2001. (Pubitemid 32226244)
24. Luo JI and Cantley LC: The negative regulation of phosphoinositide 3-kinase signaling by p85 and its implication in cancer. Cell Cycle 4: 1309-1312, 2005.
25. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
26. Day RM, Lee YH, Park A and Suzuki YJ: Retinoic acid inhibits airway smooth muscle cell migration. Am J Respir Cell Mol Biol 34: 695-703, 2006. (Pubitemid 43825334)
27. Dutta A, Sen T, Banerji A, Das S and Chatterjee A: Studies on multifunctional effect of all-trans retinoic acid (ATRA) on matrix metalloproteinase-2 (MMP-2) and its regulatory molecules in human breast cancer cells (MCF-7). J Oncol 2009: 627840, 2009.
28. Dutta A, Sen T and Chatterjee A: All-trans retinoic acid (ATRA) downregulates MMP-9 by modulating its regulatory molecules. Cell Adh Migr 4: 409-418, 2010.
29. Chen HC, Appeddu PA, Isoda H and Guan JL: Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J Biol Chem 271: 26329-26334, 1996. (Pubitemid 26347485)
30. Jones RJ, Brunton VG and Frame MC: Adhesion-linked kinases in cancer; emphasis on Src, focal adhesion kinase and PI3-kinase. Eur J Cancer 36: 1595-1606, 2000. (Pubitemid 30616364)
31. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW and Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407: 538-541, 2000.
32. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV and Auricchio F: PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 20: 6050-6059, 2001. (Pubitemid 33049280)
33. Le Romancer M, Treilleux I, Leconte N, Robin-Lespinasse Y, Sentis S, Bouchekioua-Bouzaghou K, Goddard S, Gobert-Gosse S and Corbo L: Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell 31: 212-221, 2008. (Pubitemid 352005820)
34. Cao X, Kambe F, Moeller LC, Refetoff S and Seo H: Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Mol Endocrinol 19: 102-112, 2005. (Pubitemid 40065962)
35. Ohashi E, Kogai T, Kagechika H and Brent GA: Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells. Cancer Res 69: 3443-3450, 2009.
36. Gaillard E, Bruck N, Brelivet Y, Bour G, Lalevée S, Bauer A, Poch O, Moras D and Rochette-Egly C: Phosphorylation by PKA potentiates retinoic acid receptor alpha activity by means of increasing interaction with and phosphorylation by cyclin H/cdk7. Proc Natl Acad Sci USA 103: 9548-9553, 2006. (Pubitemid 43955862)
37. Parrella E, Gianni M, Cecconi V, Nigro E, Barzago MM, Rambaldi A, Rochette-Egly C, Terao M and Garattini E: Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways. J Biol Chem 279: 42026-42040, 2004. (Pubitemid 39313654)
38. Srivastava RK, Srivastave AR and Cho-Chung YS: Synergistic effects of 8-Cl-cAMP and retinoic acids in the inhibition of growth and induction of apoptosis in ovarian cancer cells: induction of retinoic acid receptor beta. Mol Cell Biochem 204: 1-2, 2000.
39. Torella D, Gasparri C, Ellison GM, Curcio A, Leone A, Vicinanza C, Galuppo V, Mendicino I, Sacco W, Aquila I, et al: Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85 PI3K. Am J Physiol Heart Circ Physiol 297: 2015-2025, 2009.
40. Taraboletti G, Borsotti P, Chirivi RG, Vergani V, Falanga A, Barbui T, Giavazzi R and Rambaldi A: Effect of all trans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. Int J Cancer 70: 72-77, 1997. (Pubitemid 27059708)
41. Pastan IH, Johnson GS and Anderson WB: Role of cyclic nucleotides in growth control. Annu Rev Biochem 44: 491-522, 1975.
42. Lee YH, Park JS, Park CH and Lee SK: Synergistic effect of cyclic AMP and insulin on the expression of cyclin A gene in Swiss 3T3 cells. Biochem Biophys Res Commun 244: 843-848, 1998. (Pubitemid 28418157)
43. Ariga M, Nedachi T, Akahori M, Sakamoto H, Ito Y, Hakuno F and Takahashi S: Signalling pathways of insulin-like growth factor-I that are augmented by cAMP in FRTL-5 cells. Biochem J 348: 409-416, 2000. (Pubitemid 30345215)
44. Magnaldo I, Poyssegur J and Paris S: Cyclic AMP inhibits mitogen-induced DNA synthesis in hamster fibroblasts, regardless of the signalling pathway involved. FEBS Lett 245: 65-69, 1989. (Pubitemid 19076204)
45. Hecquet C, Lefevre G, Valtink M, Engelmann K and Mascarelli F: cAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner. Oncogene 21: 6101-6112, 2002.
46. Keely PJ, Westwick JK, Whitehead IP, Der CJ and Parise LV: Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 390: 632-636, 1997. (Pubitemid 28016201)
47. van Nimwegen MJ and van de Water B: Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol 73: 597-609, 2007. (Pubitemid 46161372)
48. Aronsohn MS, Brown HM, Hauptman G and Kornberg LJ: Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx. Laryngoscope 113: 1944-1948, 2003. (Pubitemid 37409682)
49. Kallergi G, Mavroudis D, Georgoulias V and Stournaras C: Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 13: 79-88, 2007. (Pubitemid 46786836)
50. Recher C, Ysebaert L, Beyne-Rauzy O, Mansat-De Mas V, Ruidavets JB, Cariven P, Demur C, Payrastre B, Laurent G and Racaud-Sultan C: Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res 64: 3191-3197, 2004. (Pubitemid 38581422)
51. Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu ET and Cance WG: Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 55: 2752-2755, 1995.
52. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE and Parsons JT: Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 20: 1152-1163, 2001. (Pubitemid 32226241)
53. Kallergi G, Agelaki S, Markomanolaki H, Georgoulias V and Stournaras C: Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells. Cell Physiol Biochem 20: 977-986, 2007. (Pubitemid 350059740)
54. Calalb MB, Polte TR and Hanks SK: Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 15: 954-963, 1995.
55. Schlaepfer DD and Hunter T: Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases. Mol Cell Biol 16: 5623-5633, 1996. (Pubitemid 26315082)
56. Wang F, Nohara K, Olivera A, Thompson EW and Spiegel S: Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate. Exp Cell Res 247: 17-28, 1999. (Pubitemid 29393958)
57. Lorch JH, Thomas TO and Schmoll HJ: Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 67: 727-734, 2007. (Pubitemid 46192213)